Aurobindo Pharma arm's New Jersey unit gets warning letter from USFDA

This follows the earlier letter dated June 4, 2020, issuing an OAI (Official Action Indicated) status for this facility.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3dN0epA
via IFTTT